Home › Calculator › ALPMY Dividend Calculator 2026
ALPMY DRIP Calculator & Dividend Yield 2026
2.81% YieldHealthcareAstellas Pharma Inc. · OTC
Price: $15.95 · Annual div: $0.4489/share · Frequency: semi-annual · Payout ratio: N/A · Ex-div: 2026-09-30
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
ALPMY Dividend Yield
ALPMY (Astellas Pharma Inc.) has a dividend yield of 2.81%, based on an annual dividend of $0.4489 per share and a price of $15.95. Over the last 12 months it paid $0.4988 per share — a trailing yield of 3.13%. Dividends are paid semi-annual.
Yield history: over the last 12 payments, ALPMY's 12-month yield ranged from 2.41% to 6.07%. Full ALPMY dividend history ↓
Yield on cost: if ALPMY's dividend keeps growing 14.5% a year, a purchase at today's price would yield 5.54% after 5 years, 10.90% after 10 years and 42.22% after 20 years on the original investment.
ALPMY DRIP Rate: How Many Shares Your Dividends Buy
With dividends reinvested, a ALPMY position grows its share count by about 2.84% in the first year at today's price and yield.
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ALPMY pays your bills
Year your monthly dividend income covers each expense (based on current settings)
ALPMY Dividend History — Last 36 Payments
| Ex-Dividend Date | Payment Date | Amount / Share | TTM Yield | Stock Price |
|---|---|---|---|---|
| 2026-09-30Latest | 2026-12-01 | $0.2550 | 3.35% | $14.90 |
| 2026-03-31 | 2026-06-18 | $0.2438 | 3.17% | $15.64 |
| 2025-09-30 | 2025-12-16 | $0.2515 | 4.59% | $11.09 |
| 2025-03-31 | 2025-06-18 | $0.2573 | 5.19% | $9.72 |
| 2024-09-30 | 2024-12-17 | $0.2467 | 3.83% | $12.30 |
| 2024-03-27 | 2024-06-17 | $0.2242 | 6.07% | $11.15 |
| 2023-09-28 | 2023-12-18 | $0.2365 | 4.44% | $15.17 |
| 2023-03-30 | 2023-06-16 | $0.2162 | 3.13% | $13.93 |
| 2022-09-29 | 2022-12-15 | $0.2202 | 2.91% | $14.20 |
| 2022-03-29 | 2022-06-15 | $0.1933 | 2.53% | $16.33 |
| 2021-09-28 | 2021-12-16 | $0.2204 | 2.41% | $17.12 |
| 2021-03-29 | 2021-06-16 | $0.1919 | 2.44% | $16.09 |
| 2020-09-28 | 2020-12-15 | $0.2011 | — | — |
| 2020-03-27 | 2020-06-15 | $0.1862 | — | — |
| 2019-09-26 | 2019-12-17 | $0.1843 | — | — |
| 2019-03-28 | 2019-07-05 | $0.1752 | — | — |
| 2018-09-27 | 2018-12-17 | $0.1673 | — | — |
| 2018-03-28 | 2018-07-03 | $0.1629 | — | — |
| 2017-09-28 | 2017-12-18 | $0.1607 | — | — |
| 2017-03-28 | 2017-07-05 | $0.1524 | — | — |
| 2016-09-27 | 2016-12-15 | $0.1488 | — | — |
| 2016-03-28 | 2016-07-01 | $0.1530 | — | — |
| 2015-09-25 | 2015-12-16 | $0.1301 | — | — |
| 2015-03-26 | 2015-07-06 | $0.1300 | — | — |
| 2014-09-25 | 2014-12-18 | $0.1185 | — | — |
| 2014-03-26 | 2014-07-03 | $0.1718 | — | — |
| 2013-09-25 | 2013-12-17 | $0.1578 | — | — |
| 2013-03-26 | 2013-07-08 | $0.1663 | — | — |
| 2012-09-25 | 2012-12-18 | $0.1973 | — | — |
| 2012-03-27 | 2012-07-09 | $0.2025 | — | — |
| 2011-09-27 | 2011-12-16 | $0.1930 | — | — |
| 2011-03-28 | 2011-07-07 | $0.2027 | — | — |
| 2010-09-27 | 2010-12-16 | $0.1778 | — | — |
| 2010-03-26 | 2010-07-12 | $0.1818 | — | — |
| 2009-09-25 | 2009-12-16 | $0.1726 | — | — |
| 2009-03-26 | 2009-07-09 | $0.1573 | — | — |
About Astellas Pharma Inc. (ALPMY) — Dividend Analysis 2026
Astellas Pharma Inc. operates as a global pharmaceutical enterprise, specializing in the research, development, manufacturing, and commercialization of a broad spectrum of medicinal products worldwide. The company's diverse pipeline and marketed portfolio address critical unmet medical needs across various therapeutic areas. In oncology, Astellas offers XTANDI, an androgen receptor signaling inhibitor used in prostate cancer; XOSPATA, a FLT3 inhibitor designed for adults with relapsed or refractory acute myeloid leukemia characterized by a FLT3 mutation; and PADCEV, a treatment option for patients with locally advanced or metastatic urothelial cancer. For urological conditions, key offerings include Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist managing urgency, urinary frequency, and urge urinary incontinence, alongside Vesicare for overactive bladder and mirabegron specifically for pediatric neurogenic detrusor overactivity. Other urology-related products include Eligard for prostate cancer and Harnal/Omnic for benign prostatic hyperplasia. Beyond oncology and urology, the company provides Evrenzo, an oral medication for anemia linked to chronic kidney disease, and the immunosuppressant family Prograf/Advagraf/Graceptor/ASTAGRAF, vital for preventing organ rejection in transplant recipients. Funguard/MYCAMINE serves as an antifungal agent. Astellas actively engages in numerous strategic collaborations to expand its innovation pipeline. These include clinical trial partnerships with Merck & Co., Inc. and CytomX Therapeutics, Inc., as well as an innovative agreement with BANDAI NAMCO Entertainment Inc. to develop a smartphone-based exercise support application. Further alliances encompass a strategic research partnership with Harvard University focused on therapeutics and technologies, a research collaboration with Actinium Pharmaceuticals, Inc. to advance targeted radiotherapies using its Antibody Warhead Enabling platform, and an agreement with Zenith Epigenetics Ltd. for the evaluation of ZEN-3694. The company also maintains a collaboration with Cytokinetics, Incorporated, and has forged a strategic partnership and license agreement with Minovia Therapeutics Ltd. to develop cell therapy programs addressing diseases stemming from mitochondrial dysfunction. Founded in 1923, Astellas Pharma Inc. maintains its corporate headquarters in Tokyo, Japan.
ALPMY Dividend & DRIP — Frequently Asked Questions
What is ALPMY's dividend yield?
ALPMY (Astellas Pharma Inc.) has a dividend yield of 2.81%, based on an annual dividend of $0.4489 per share and a price of $15.95. Over the last 12 months it paid $0.4988 per share — a trailing yield of 3.13%. Dividends are paid semi-annual.
How much does $10,000 in ALPMY pay in dividends?
$10,000 in ALPMY at a 2.81% yield pays about $281 a year ($23 a month) before taxes. With DRIP, reinvested dividends buy more shares and that income compounds.
What is the DRIP rate for ALPMY?
With dividends reinvested, a ALPMY position grows its share count by about 2.84% in the first year at today's price and yield.
How do I calculate ALPMY dividend reinvestment (DRIP) returns?
Enter your starting amount, monthly contribution and time horizon in the ALPMY DRIP calculator at the top of this page. It reinvests each payout into new shares at the projected price, grows the dividend at the rate you choose and shows yearly income, share count, portfolio value and yield on cost. You can switch DRIP off to compare.
When is ALPMY's next ex-dividend date?
ALPMY's next ex-dividend date has not been announced yet; the most recent one was 2026-09-30. ALPMY pays dividends semi-annual. Buy before the ex-dividend date to receive the next payment.
What is ALPMY's dividend growth rate?
ALPMY's dividend changed -2.0% over the last year and 14.5% a year on average over five years.
Similar dividend stocks to ALPMY
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ALPMY DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ALPMY position with:
🌍 ALPMY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ALPMY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.81% | 0.01% | $281 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.39% | -0.41% | $239 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2.25% | -0.55% | $225 / yr |
| 🇬🇧 UK ISA | 0% | 2.81% | 0.01% | $281 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.56% | -0.24% | $256 / yr |
| 🇨🇦 TFSA | 0% | 2.81% | 0.01% | $281 / yr |
| 🇨🇦 CA Taxable | 25% | 2.11% | -0.69% | $211 / yr |
| 🇦🇺 Super (pension) | 15% | 2.39% | -0.41% | $239 / yr |
| 🇦🇺 AU Taxable | 30% | 1.97% | -0.83% | $197 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2.07% | -0.73% | $207 / yr |
| 🇫🇷 FR Taxable | 30% | 1.97% | -0.83% | $197 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ALPMY Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.45/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ALPMY Dividend Payment Schedule
ALPMY pays quarterly — 4 times per year. Ex-div: 2026-09-30.
📊 ALPMY vs Healthcare Benchmarks
How ALPMY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ALPMY sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ALPMY Insider Activity
No recent SEC filings reported in the last 90 days.Peer Group
Similar companies in the same sectorCompare ALPMY with peers: ALPMY vs BMXXY · ALPMY vs CHJTF · ALPMY vs GIKLY
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ALPMY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Astellas Pharma Inc. (ALPMY) is currently trading at $15.95, 8% below its 52-week high. The current dividend yield is 2.81% based on an annual payout of $0.4489 per share.
ALPMY (Astellas Pharma Inc.) — 2.81% Dividend Yield Analysis
Astellas Pharma Inc. (ALPMY) is a healthcare stock currently trading at $15.95 with a dividend yield of 2.81%. It pays an annual dividend of $0.4489 per share. Over the past 5 years, ALPMY has grown its dividend at a compound annual rate of 14.5%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest ALPMY News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.
How investors use the ALPMY dividend calculator
Illustrative examples of common use cases, written by the DividendFlow team — not customer reviews.